CU Medical Systems Inc

The company maintains a relatively strong liquidity position, with cash and equivalents amounting to KRW 18.56 billion, which is 46.4% of total assets. However, its net cash position is negative after subtracting total debt, indicating a potential liquidity risk. The current ratio of 4.84 suggests the company has sufficient short-term assets to cover its short-term liabilities. The price-to-book ratio of 0.56 indicates that the company's market value is below its book value, which may reflect market skepticism or undervaluation. Profitability metrics show a return on equity (ROE) of 1.37% and a return on assets (ROA) of 0.82%, both of which are below the typical thresholds for high-performing healthcare equipment firms. The operating margin is 22.4%, calculated as operating income of KRW 10.81 billion divided by revenue of KRW 48.22 billion, which is in line with industry norms. The net profit margin is 1.7%, reflecting a net income of KRW 819.20 million on total revenue. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may increase exposure to regional or sector-specific risks. The company's revenue growth trajectory is not explicitly provided in the available data, but the current fiscal year outlook does not indicate a significant change in direction. The capital expenditure of KRW 776.17 million in the latest period suggests a modest investment in long-term assets. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.56 suggests a moderate level of leverage, which is generally acceptable for a healthcare equipment firm. However, the negative net cash position after subtracting total debt is a key flag that may require further monitoring. Recent events, including filings and transcripts, are not detailed in the provided data, so no specific recent developments can be cited.